Molefy Pharma was founded in 2024 with the vision of transforming the future of healthcare. Born from the collaboration between CSIC and ARQUIMEA, we are driven by an unprecedented commitment to research and innovation. Our mission is clear: to revolutionize the treatment of neurodegenerative diseases with breakthrough therapies that challenge the status quo and offer new hope to patients.
The Spanish National Research Council (CSIC) is Spain’s leading public research institution and one of the most renowned in Europe. Dedicated to advancing scientific knowledge and technological innovation, CSIC plays a key role in bridging the gap between fundamental research and real-world applications through successful technology transfer initiatives.
ARQUIMEA is a Spanish technology company operating globally, providing innovative solutions and products in highly demanding sectors such as Aerospace, Defense & Security, Science Industry, and Fintech. With a strong commitment to research and development, ARQUIMEA fosters cutting-edge innovation through strategic collaborations.
Developed through a successful technology transfer between ARQUIMEA, the Spanish National Research Council (CSIC), and leading scientists, Molefy Pharma is bringing cutting-edge research closer to patients.
By combining scientific excellence with an agile, industry-driven approach, Molefy Pharma is working to bring new alternatives to ALS patients through innovative drug development.
Our team at Molefy Pharma represents the perfect blend of scientific excellence and business expertise. With some of the leading minds in the field of biotechnology and a highly specialized team with deep industry experience, we are committed to pushing the boundaries of medical research. Together, we bring a powerful mix of innovation, determination, and vision to drive our mission forward.
To develop breakthrough therapies for neurodegenerative diseases, halting progression and restoring health, driven by innovation and a commitment to patients.
To create a world where neurodegenerative diseases are no longer a threat, bringing transformative solutions that restore hope to patients worldwide